Pivotal Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon (ILLUMENATE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01858428 |
Recruitment Status :
Completed
First Posted : May 21, 2013
Results First Posted : January 17, 2018
Last Update Posted : August 24, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Peripheral Arterial Disease | Device: Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter Device: EverCross Percutaneous Transluminal Balloon Catheter | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 300 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | ILLUMENATE Pivotal: ProspectIve, Randomized, SingLe-Blind, U.S. MuLti-Center Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon |
Actual Study Start Date : | June 18, 2013 |
Actual Primary Completion Date : | September 2016 |
Actual Study Completion Date : | March 19, 2018 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Bare PTA
The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
|
Device: EverCross Percutaneous Transluminal Balloon Catheter
The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA). |
Experimental: Drug-Coated PTA
The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
|
Device: Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter
The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier. |
- Patency at 12 Month Post-procedure [ Time Frame: 12 months ]Patency is defined as the absence of target lesion restenosis as determined by duplex ultrasound (Peak Systolic Velocity Ratio (PSVR) ≤ 2.5) and freedom from clinically-driven target lesion revascularization.
- Freedom From Device and Procedure-related Death and Target Limb Major Amputation and Clinically-driven Target Lesion Revascularization [ Time Frame: 30 Days and 12 months ]Freedom from device and procedure-related death through 30 days post-procedure and freedom from target limb major amputation and clinically-driven target lesion revascularization through 12 months post-procedure.
- Major Adverse Event (MAE) Rate in the Hospital and at 1, 6, 12, 24, 36, 48 and 60 Months Post-procedure [ Time Frame: 1, 6, 12, 24, 36, 48 and 60 months ]Major adverse event (MAE) rate in the hospital and at 1, 6, 12, 24, 36, 48 and 60 months post-procedure, defined as a composite rate of cardiovascular death, target limb major amputation and clinically-driven target lesion revascularization (TLR).
- Rate of Vascular Access and Bleeding Complications [ Time Frame: in-hospital and 1, 6, 12 and 24 months ]Rate of vascular access and bleeding complications in the hospital and at 1, 6, 12 and 24 months.
- Rate of Clinically-driven Target Lesion Revascularization [ Time Frame: 6, 12, 24, 36, 48 and 60 months ]
- Rate of Target Lesion Revascularization [ Time Frame: 6, 12, 24, 36, 48 and 60 months ]
- Rate of Target Limb Major Amputation [ Time Frame: 1, 6, 12, 24, 36, 48 and 60 months ]
- Mortality Rate [ Time Frame: 6, 12, 24, 36, 48 and 60 months ]
- Rate of Occurrence of Arterial Thrombosis of the Treated Segment [ Time Frame: 1, 6, 12, 24, 36, 48 and 60 months ]
- Patency Rate and Freedom From Clinically-driven TLR [ Time Frame: 6, 24 and 36 months ]Patency rate defined as the absence of target lesion restenosis as determined by duplex ultrasound (PSVR ≤ 2.5) and freedom from clinically-driven TLR at 6, 24 and 36 months
- Lesion Success of Achieving a Final In-lesion Residual Diameter Stenosis of ≤50% [ Time Frame: procedure, Day 0 ]Lesion success, defined as achievement of a final in-lesion residual diameter stenosis of ≤50% (as determined by the angiographic core lab), using any device after wire passage through the lesion.
- Technical Success of Achieving a Final In-lesion Residual Diameter Stenosis of ≤50% [ Time Frame: procedure, Day 0 ]Technical success, defined as achievement of a final in-lesion residual diameter stenosis of ≤50% (as determined by the angiographic core lab), using the CVI Paclitaxel-coated PTA Catheter or bare balloon catheter without a device malfunction after wire passage through the lesion.
- Per Subject Clinical Success Achieving no Major Adverse Events During the Procedure [ Time Frame: procedure, Day 0 ]Clinical success (per subject) defined as technical success without the occurrence of major adverse events during the procedure.
- Per Subject Procedural Success Achieving no Major Adverse Events During the Procedure [ Time Frame: procedure, Day 0 ]Procedural success (per subject) defined as lesion success without the occurrence of major adverse events during the procedure.
- Change in Ankle-brachial Index (ABI) From Pre-procedure [ Time Frame: 6, 12, 24 and 36 months ]Subjects who had reinterventions were included in ABI analyses so some improvements may be reflective of revascularizations during the follow-up period.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects with symptomatic leg ischemia, requiring treatment of the Superficial Femoral Artery (SFA) or popliteal artery.
Exclusion Criteria:
- Known intolerance to study medications, paclitaxel or contrast agents that in the opinion of the investigator cannot be adequately pre-treated

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01858428

Principal Investigator: | Prakash Krishnan, MD | Mt. Sinai Medical Center | |
Principal Investigator: | Sean Lyden, MD | The Cleveland Clinic |
Responsible Party: | Spectranetics Corporation |
ClinicalTrials.gov Identifier: | NCT01858428 |
Other Study ID Numbers: |
TP-1397 |
First Posted: | May 21, 2013 Key Record Dates |
Results First Posted: | January 17, 2018 |
Last Update Posted: | August 24, 2020 |
Last Verified: | August 2020 |
Peripheral Arterial Disease Peripheral Vascular Diseases Atherosclerosis Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Cardiovascular Diseases |
Paclitaxel Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |